Herbert Cruz
Psychiatry · Fresno, CANPI 1023107513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $313,067 of the $393,577 with a category attached, or 79.5%. Neurocrine Biosciences, Inc. accounts for 73.5% of it on its own, with 19 other manufacturers making up the rest. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $632.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$289K
- Teva Pharmaceuticals USA, Inc.$81K
- Alkermes, Inc.$14K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Otsuka America Pharmaceutical, Inc.$952
- plus $3K from 14 others
What the payments were for
- Consulting fees$36,6149%
- Speaking & faculty fees$313,06780%
- Travel & lodging$27,2047%
- Food & beverage$16,3614%
- Education$3320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 266 | $289,149 |
| Teva Pharmaceuticals USA, Inc. | 78 | $81,096 |
| Alkermes, Inc. | 122 | $14,477 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $2,889 |
| E.r. Squibb & Sons, L.L.C. | 10 | $1,877 |
| Otsuka America Pharmaceutical, Inc. | 29 | $952 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $579 |
| Johnson & Johnson | 8 | $365 |
| AbbVie(2 entities) | 16 | $325 |
| Axsome Therapeutics, Inc. | 5 | $298 |
| Indivior Inc. | 9 | $274 |
| Braeburn Inc. | 7 | $242 |
| Vanda Pharmaceuticals Inc. | 7 | $225 |
| Lundbeck LLC | 10 | $182 |
| Sunovion Pharmaceuticals Inc. | 7 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $158 |
| Bioxcel Therapeutics, Inc. | 1 | $125 |
| Gilead | 1 | $116 |
| Avanir Pharmaceuticals, Inc. | 3 | $66 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$286,066
- AUSTEDO$75,406
- VIVITROL$11,975
- Austedo XR$4,688
- LYBALVI$1,477
- ARISTADA$967
- ABILIFY MAINTENA$368
- COBENFY$250
- REXULTI$221
- Fanapt$126
- ARISTADA INITIO$125
- UZEDY$125
- ABILIFY ASIMTUFII$125
- IGALMI$125
- Auvelity$125
- CAPLYTA$125
- PERSERIS$123
- BRIXADI$122
- Biktarvy$116
- SPRAVATO$104
How this compares
$393,577 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 40 | $322,461 |
| NuedextaDextromethorphan Hbr/Quinidine | 62 | $101,697 |
| LybalviOlanzapine/Samidorphan Malate | 42 | $67,230 |
| VraylarCariprazine Hcl | 26 | $36,476 |
| Asenapine Maleate | 58 | $30,976 |
| CaplytaLumateperone Tosylate | 16 | $28,234 |
| Chlorpromazine Hcl | 14 | $25,675 |
| Clomipramine Hcl | 73 | $23,509 |
| Fluvoxamine Maleate | 66 | $8,906 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $7,442 |
| Quetiapine Fumarate | 131 | $6,365 |
| Divalproex Sodium | 63 | $5,562 |
| BelsomraSuvorexant | 12 | $4,998 |
| Clozapine | 60 | $4,266 |
| Risperidone | 105 | $3,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $289,149 | $322,46140 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $66 | $101,69762 claims |
| Alkermes, Inc.Lybalvi | $14,477 | $67,23042 claims |
| AbbVieVraylar | $325 | $36,47626 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $579 | $28,23416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Fresno
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.